Evidence map›Paper›PMID 19254954›Full record

ArticleThe Journal of biological chemistry2009

Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.

Tatsunori Okamura, Simendra Singh, John Buolamwini, Timothy Haystead, Henry Friedman, Darell Bigner, Francis Ali-Osman

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. GlutathioneFrontiers in immunology · 2018
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Regional treatment strategies for in-transit melanoma metastasis.Surgical oncology clinics of North America · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Tatsunori OkamuraFrom the Departments of Surgery, Durham, North Carolina 27710.
Simendra SinghFrom the Departments of Surgery, Durham, North Carolina 27710.
John BuolamwiniDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee 38163.
Timothy HaysteadPharmacology, Durham, North Carolina 27710.
Henry FriedmanFrom the Departments of Surgery, Durham, North Carolina 27710.
Darell BignerPathology, Duke Comprehensive Cancer Center, and the Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina 27710.
Francis Ali-OsmanFrom the Departments of Surgery, Durham, North Carolina 27710. Electronic address: francis.aliosman@duke.edu.
Durham Technical Community College · USDuke University · USUniversity of Tennessee Health Science Center · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
TEMODAR RESISTANCE IN CENTRAL NERVOUS SYSTEMP50CA108786 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 2004 to 2009
$12.3M
Novel Targeted Therapeutics for CNS MalignanciesR01CA112519 · NCI · DUKE UNIVERSITY · PI ALI-OSMAN, FRANCIS · 2006 to 2010
$1.7M
Protein Kinase C and GSTP1 interactions in glioma drug resistanceR01CA127872 · NCI · DUKE UNIVERSITY · PI ALI-OSMAN, FRANCIS · 2008 to 2012
$1.6M
NCI NIH HHS P30 CA014236NCI NIH HHS P30-CA14236NCI NIH HHS P50 CA108786NCI NIH HHS P50CA108786NCI NIH HHS R01 CA 112519NCI NIH HHS R01 CA112519NCI NIH HHS R01 CA127872
6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) gene amplification, mutations, and/or aberrant activation are frequent abnormalities in malignant gliomas and other human cancers and have been associated with an aggressive clinical course and a poor therapeutic outcome. Elevated glutathione S-transferase P1 (GSTP1), a major drug-metabolizing and stress response signaling protein, is also associated with drug resistance and poor clinical outcome in gliomas and other cancers. Here, we provide evidence that GSTP1 is a downstream EGFR target and that EGFR binds to and phosphorylates tyrosine residues in the GSTP1 protein in vitro and in vivo. Mass spectrometry and mutagenesis analyses in a cell-free system and in gliomas cells identified Tyr-7 and Tyr-198 as major EGFR-specific phospho-acceptor residues in the GSTP1 protein. The phosphorylation increased GSTP1 enzymatic activity significantly, and computer-based modeling showed a corresponding increase in electronegativity of the GSTP1 active site. In human glioma and breast cancer cells, epidermal growth factor stimulation rapidly increased GSTP1 tyrosine phosphorylation and decreased cisplatin sensitivity. Lapatinib, a clinically active EGFR inhibitor, significantly reversed the epidermal growth factor-induced cisplatin resistance. These data define phosphorylation and activation of GSTP1 by EGFR as a novel, heretofore unrecognized component of the EGFR signaling network and a novel mechanism of tumor drug resistance, particularly in tumors with elevated GSTP1 and/or activated EGFR.

Indexed as

Amino Acid SequenceAnimalsAntineoplastic AgentsBase SequenceBinding SitesBreast NeoplasmsCell-Free SystemCell Line, TumorCisplatinDrug Resistance, NeoplasmEnzyme ActivationErbB ReceptorsFemaleGliomaGlutathione S-Transferase piHumansAntineoplastic AgentsCisplatinErbB ReceptorsGlutathione S-Transferase piGSTP1 protein, humanLapatinibQuinazolinesRecombinant ProteinsRNA, Small InterferingTyrosine

Identifiers

PMID19254954
PMCPMC2719335
OpenAlexW1999791629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.